John P. Micha, MD

John P. Micha, MD, FACOG attended Medical School at Cornell University Medical College. He also completed his Internship and Residency in Gynecology and Obstetrics at Cornell University. He performed a Fellowship in Intensive Care Unit Medicine at Memorial Sloan Kettering Cancer Center followed by a Fellowship in Gynecologic Oncology at the University of California, Irvine. He is a Fellow of the American College of Obstetrics and Gynecology.  Dr. Micha has held faculty appointments at the University of California at Los Angeles, the City of Hope Medical Center and at the University of Southern California.  He is the current chairman of the Womens Cancer Research Foundation.

Download and Print New Patient Forms

BUSINESS ADDRESS
Gynecologic Oncology Associates
351 Hospital Road
Suite 507
Newport Beach, CA  92663
Phone: (949) 642-1361

EDUCATION
College:
Reed College Portland, Oregon Liberal Arts 1968-1970
State University of New York at Buffalo
Buffalo, New York
Bachelor of Science Degree: Biology 1970 – 1972

Medical School:
Cornell University Medical College
New York, New York
Medical Doctor Degree: May 1977 1973-1977

Internship: Cornell University Medical Center New York Hospital Flexible Medicine July 1977 – June 1978

Residency: Cornell University Medical Center New York Hospital Department of Obstetrics and Gynecology July 1978 – June 1981

Administrative Chief Resident: Cornell University Medical Center New York Hospital Department of Obstetrics and Gynecology July 1980 – June 1981 Chairman: Dr. William Ledger

Fellowship: Memorial Sloan Kettering Cancer Center Intensive Care Unit New York City, New York Critical Care Fellow September 1981 – November 1981

University of California, Irvine Medical Center Gynecologic Oncology Research Fellow July 1982 – June 1983

University of California, Irvine Medical Center Gynecologic Oncology Clinical Fellow July 1983 – June 1985

MEDICAL LICENSURE California: #G47274 (1982) New York: #135943 (1978) California Fluoroscopy X-ray Supervisor and Operator: #129443 (1988)

SPECIALTY CERTIFICATION American Board of Obstetrics and Gynecology Board Certified: #815389O (1987) recertified (1998)

American Board of Obstetrics and Gynecology Gynecologic, Oncology Subspecialty Board Certified: #815389O (1988) recertified (1998)

PROFESSIONAL BACKGROUND 1. ACADEMIC APPOINTMENTS a. UCLA Department of Obstetrics and Gynecology Division of Gynecologic Oncology Clinical Associate Professor 1986 – 1992

b. University of California, Irvine Medical Center Department of Obstetrics and Gynecology Clinical Instructor Chairman: Dr. Philip DiSaia 1982 – 1985

c. City of Hope National Medical Center Department of Surgery Division of Gynecologic Oncology Acting Director of Gynecologic Oncology July – September 1985

d. Cornell University Medical Center Department of Obstetrics and Gynecology Full Time Faculty Clinical Instructor Chairman: Dr. William Ledger 1981 – 1982

e. Director of Gynecologic Oncology Irvine Medical Center Irvine, California 1986 – 1990

f. Director of Gynecologic Education Saint Joseph Hospital Orange, California 1986 – Present

AWARDS 1. ACOG/Ortho Fellowship Research Award for 1982 – 1983 American College of Obstetricians and Gynecologists

2. University of California, Irvine Medical Center Annual Residents and Fellows Research Prize for 1985 “Human Lymphoblastoid Interferon Treatment of Persistent Condyloma Acuminata.” Moderator: Dr. E.J. Quilligan

3. American Cancer Society Clinical Fellow July 1984 – July 1985

4. “Fellow of the Year Award” for 1985 University of California, Irvine Department of Obstetrics and Gynecology Presented by the Chief of Residents

5. Named as “One of the Best Physicians in Orange County” Orange Coast Magazine, March 1998 Compiled by polling Orange County physicians

6. Physician of the Month for December 2000 Hoag Hospital, 5th Floor

7. Best Doctor 2001-2002 (Orange Coast)

8. America’s Top Obstetricians and Gynecologists 2002-2003 (Consumers Research Council of America)

9. Best Doctor 2003-2004 (Orange Coast)

10. America’s Top Obstetricians and Gynecologists 2004-2005 (Consumers Research Council of America)

11. America’s Top Physician 2004-2005 (Consumers Research Council of America)

12. Top Doctors 2004 (Orange Coast)

13. Best Doctor 2005-2006 (Orange County Medical Society & Orange Coast)

14. America’s Top Obstetricians and Gynecologists 2006 (Consumers Research Council of America)

ASSOCIATION MEMBERSHIPS 1. American College of Obstetricians and Gynecologists (Fellow) (1981) 2. American Cancer Society (1982) 3. California Medical Review (Peer Review Organization) (1985) 4. American Society of Clinical Oncologists (1987) 5. Society of Gynecologic Oncologists (1985) 6. Western Association of Gynecologic Oncologists (1987) 7. American Medical Fly Fishing Association (1992-1996) 8. International Gynecologic Cancer Society (2005-2007)

RESEARCH: FULL TIME LABORATORY 1. Projects: Undergraduate Isolation of the Acetyl Choline Receptor from Striated Muscle January 1972 – June 1972 Full time Laboratory Assistant Department of Biochemistry State University of New York at Buffalo Muscular Dystrophy Association Grant

2. Projects: Postgraduate University of California, Irvine Medical Center Gynecologic Oncology Research Fellow July 1982 – June 1983

3. Research Awards ACOG/Ortho Research Fellowship Award for 1982 – 1983 American College of Obstetricians and Gynecologists University of California, Irvine Medical Center 1984 Annual Residents and Fellows Research Prize “Human Lymphoblastoid Interferon Treatment of Persistent Condyloma Acuminata.” Moderator: Dr. E.J. Quilligan Fellow of the Year 1985 (Senior Resident)

RESEARCH: CLINICAL 1. Principal Investigator, UCLA/Hoag Hospital Cancer Center Gynecologic Oncology Group 1985 – 1995

2. Principal Investigator, University of Oregon/Hoag Hospital Cancer Center Gynecologic Oncology Group 1995 – 1997

RESEARCH: GRANTS 1. ACOG/Ortho Research July 1982 – July 1983 Fellowship Award

2. Burroughs Wellcome Grant “Human Lymphoblastoid Interferon Treatment of Recurrent Condyloma Acuminata” July 1983 – July 1984

3. Miles Pharmaceuticals Grant “Phophylactic Mezlocillin versus Placebo in Radical Hysterectomy Patients” September 1983 – June 1985

4. American Cancer Society July 1984 – July 1985 Clinical Fellow

5. Miles Pharmaceuticals Grant “Mezlocillin versus Gentamicin/Cleocin for the Treatment of Pelvic Inflammatory Disease.” 1985 – 1987

6. Pharmaquest Grant “Thiamphenicol in the Treatment of Pelvic Inflammatory Disease.” 1987

7. Oclassen Pharmaceuticals “New Drug Approaches to the Treatment of Condyloma Acuminata.” 1987

8. Bristol Myers Grant “BMY – 28100 in the Treatment of Uncomplicated Lower Urinary Tract Infections.” 1987

9. Oclassen Pharmaceuticals Condylox Therapy of Patients with Condyloma Acuminata 1989

10. Bristol Myers Grant      3 Hour Taxol/Carboplatinum First Line      Treatment of Patients with Stage III/IV      Ovarian Adenocarcinoma 1993

Bristol Myers Grant (continued)     1 Hour Taxol/Carboplatinum First Line     Treatment of Patients with Stage III/IV     Ovarian Adenocarcinoma 1995

11. Amgen Carboplatinum/Cytoxan/Neupogen First Line Treatment of Patients with Stage III/IV Ovarian Adenocarcinoma 1992

12. Smith Kline Beecham 3 Day Topotecan Second Line Treatment of Patients with Recurrent Ovarian Adenocarcinoma 1997

13. Eli Lilly Gemzar/Taxol/Carboplatinum First Line Treatment of Patients with Stage III/IV Ovarian Adenocarcinoma 1997

14. St. Joseph Hospital Cancer Center Clinical Research Grant 1995

15. Hoag Hospital Cancer Center Clinical Research Grant 1995-2004

16. Genentech Gemzar/Taxol/Avastin First Line Treatment of Patients with Stage III/IV Ovarian Adenocarcinoma 2004

17. Cellpath Phase II Trial of Digitoxin in Patients with Recurrent Epithelial Mullerian Adenocarcinoma 2000

18. Eli Lilly Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced, Persistent, or Recurrent Carcinoma of theCervix 2001

19. Ortho Biotech A Phase II Trial of Doxil and Carboplatin for the Treatment of Advanced, Recurrent, or Persistent Endometrial Carcinoma 2002

20. Altarex A randomized, double-blind, placebocontrolled, phase IIB study of the safety and efficacy of OvaRex (MAb-B43.13) in ovarian cancer patients with an elevated serum CA-125 but without other evidence of disease 2000

21. Altarex A multi-center clinical trial of intravenous OvaRex (MAb-B43.13) as post chemotherapy consolidation for ovarian, tubal and peritoneal carcinoma 2000

22. Atairgin Technologies, Inc. A clinical protocol to evaluate the role of lysophosphatidic acid as an aid in the differential diagnosis of ovarian cancer in women scheduled for surgery with a pelvicmass or a suspected ovarian malignancy 2001

23. Atairgin Technologies, Inc A protocol to characterize lysophosphatidic acid assay levels in women not suspected of ovarian cancer 2001

24. Eli Lilly A Randomized Phase III Trial of Gemzar versus Doxil with Crossover Treatment Option for Patients with Platinum-Resistant Ovarian, Fallopian Tube, Peritoneal Cancer 2002

25. GlaxoSmithKline A Phase II, Multi-Center Trial of Weekly Topotecan in Patients With Recurrent Platinum Sensitive Epithelial Cancers of the Ovary, Fallopian Tube, and Peritoneum 2003

26. The ANC Study Group The ANC Study Group Registry: A Prospective Study of Neutropenic Complications 2002

27. Amgen A Randomized, Open-Label Study to Assess Time to Hemoglobin Response of a Front Load Dosing Regimen for Darbepoetin Alfa Compared to a Weekly Dose Regimen for Recombinant Human Erythropoietin in Patients with Non-Myeloid Malignancies Receiving Chemotherapy 2003

28. Unither A Double Blind, Placebo-Controlled, Multicenter Clinical Trial Of Intravenous OvaRex Mab-B43.13 As Post-Chemotherapy Consolidation For Epithelial Carcinoma Of Ovarian, Tubal Or Peritoneal Origin 2003

29. Telik Phase 3 Randomized Study of TLK286 versus Doxil/Caelyx or Hycamptin as Third-Line Therapy in Platinum Refractory or resistant Ovarian Cancer 2003

30. Cell Therapeutics CT-2103/Carboplatin for Patients with Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase II Study 2004

31. Cell Therapeutics Phase I/II study of PG Taxol (CT-2103) in Patients with Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer 2001

32. Amgen Filgrastim as an Adjunct to Cyclophosphamide and Carboplatin Chemotherapy in Advanced Ovarian Carcinoma 1993

33. Genentech Gemzar/Taxol/Avastin First Line Treatment (Weekly) of Patients with Stage III/IV Ovarian Adenocarcinoma 2007

PUBLICATIONS (PEER REVIEW JOURNALS)

1. Fuchs, A; Husslein, P; Sumulong, L; Micha, JP; Dawood, MY; Fuchs, F: Plasma levels of oxytocin and 13, 14-dihydro-15-keto prostagladin F2 alpha in preterm labor and the effect of ethanol and ritodrine. Am J Obstet Gynecol; 133: 753-759, 1982.

2. Stratton, JA; Micha, JP; Braly, PS; Rettenmaier, MA; Berman, ML; DiSaia, PJ: The response of gynecologic tumors to chemotherapy: Correlation of the chemosensitivity predicted by the subrenal capsule implant assay with the clinical responses of the patients. Thirteenth International Congress of Chemotherapy. (Ed. K.H. Spitzy and K. Karrer) 11: 123-126, 1983.

3. Micha, JP; Qyunbt, F: Baboon cervical colposcopy, histology, and cytology. Gynecol Oncol; 17: 308-318, 1984

4. Stratton, JA; Micha, JP; Rettenmaier, MA; Braly, PS; DiSaia, PJ: Chemosensitivity testing of nonsolid tumors by the subrenal capsule implant assay. Gynecol Oncol; 17: 105-108, 1984.

5. Berman, ML; Miller, RD; Branson, HE; Kucera, PR; Micha, JP; Thrupp, LD; Boutry, RS: Prospective evaluation of coagulation profiles of patients treated with Cefotetan or Moxalactam. J Therapeutic Research; 36: 893-901, 1984.

6. Stratton, JA; Kucera, PR; Micha, JP; Rettenmaier, MA; Braly, PS; Berman, ML; DiSaia, PJ: The subrenal capsule tumor implant assay as a predictor of clinical response to chemotherapy: Three years of experience. Gynecol Oncol; 19: 336-347, 1984.

7. Micha, JP; Kucera, PR; Preve, C; Rettenmaier, MA; Stratton, JA; Disaia, PJ: Action of 2-beta-D-ribofuranosylthiazole-4 carboxamide (tiazofurin) against untreated ovarian cancers in the murine xenograft assay. Gynecol Oncol; 21: 351-355, 1985.

8. Rettenmaier, MA; Micha, JP; Kucera, PR; Berman, ML; Disaia, PJ: A simplified method of right atrial catheter insertion. Gynecol Oncol; 21: 207-210, 1985.

9. Micha, JP; Kucera, PR; Berman, ML; Romansky, S; Flamm, M; Reynolds, J; DiSaia, PJ: Malignant ovarian germ cell tumors: A review of 36 cases. Am J Obstet Gynecol; 152: 842-846, 1985.

10. Berkeley, A; Micha, JP; Freedman, KS; Hirsch, J: The potential of digitally inserted tampons to induce vaginal lesions. Obstet Gynecol; 66: 31, 1985.

11. Silva, PD; Micha, JP, Silva, DG: Management of condyloma acuminata. J Amer Academy Dermatol; 13(3): 457-463, 1985.

12. Rettenmaier, MA; Micha, JP; Braly, PS; Silva, PD; Berman, ML; DiSaia, PJ: A semi-permanent right atrial catheter in gynecologic cancer patients. Obstet Gynecol; 66: 559, 1985.

13. King, M; Micha, JP; Allen, SL; Mouradian, JA; Chaganti, RSK: Immature teratoma of the ovary, with predominant retinal anlage component. American Journal of Surgical Pathology 1985; 9:221-231.

14. Micha, JP; Kucera, PR; DiSaia, PJ: Human lymphoblastoid interferon treatment Of recurrent condyloma acuminata. Obstet Gynecol 1986; 11: 231-233.

15. Stratton, JA; Kucera, PR; Rettenmaier, MA; Micha, JP; Braly, PS; Berman, ML; DiSaia, PJ: Accurate laboratory predictions of the clinical response of advanced ovarian cancer patients to treatment with cyclophosphamide, doxorubicin and cisplatin. Gynecol Oncol; 25: 302, 1986.

16. Micha, JP; Kucera, PR; Birkett, JP; Chambers, G; Sheets, EE; DiSaia, PJ: Prophylactic mezlocillin in Radical Hysterectomy. Obstet Gynecol; 69: 251-254, 1987.

17. Reichman RC, Micha JP, Weck PK, Bonnez W, Wold D, Whisnant JK, Mounts P, Trofatter KF, Kucera P, Gall SA.Interferon alpha-n1 (Wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapy.Antiviral Res 1988; 10:41-57.

18. Karram, M; Tabor, B; Smotkin, D; Wettstein, F; Bhatia, N; Micha, JP: Detection of human papillomavirus deoxyribonucleic acid from vulvar dystrophies and VIN lesions. Amer Jour Obstet Gynecol; 159: 22-23, 1988.

19. Chien, RTY; Rettenmaier, MA; Micha, JP; DiSaia, PJ: Ovarian epithelial tumors of low malignant potential. Surg Gynecol Obstet; 169: 143-146, 1989.

20. Rettenmaier, MA; Casanova, DM; Micha, JP; Moran, MF; Ramsinghani, NS; Syed, NA; Puthawala, A; DiSaia, PJ: Radical hysterectomy and tailored postoperative radiation therapy in the management of bulky Stage IB cervical cancer. Cancer: 63: 2220-2223, 1989.

21. Kucera, PR; Sheets, EE; Micha, JP; Rettenmaier, MA; Berman, ML; Colman, M; DiSaia, PJ: Whole abdominal radiotherapy in patients with minimal residual epithelial ovarian cancer. Gynecol Oncol; 36:338-342, 1990.

22. Baker DA, Douglas JM Jr, Buntin DM, Micha JP, Beutner KR, Patsner B. Topical podofilox for the treatment of condylomata acuminata in women. Obstet Gynecol. 1990 Oct;76(4):656-9.

23. Karram, M; Grauer, N; Micha, JP; Bhatia, N; Gunning, J: Efficacy of Mezlocillin vs Gentamicin-Clindamycin in the treatment of acute pelvic inflammatory disease. Gynecol Oncol 1992; 34: 316-18.

24. Micha, JP: Paclitaxel Delivered as a 3 Hour Infusion with Cisplatin in Patients with Gynecologic Cancers: Unexpected Incidence of Neurotoxocity. Gynecol Oncol; 66:338, 1997

25. Micha, JP; Rettenmaier, MA; Dillman, R; Fraser, P; Birk, C; Brown, JV: Single Dose Dexamethasone Taxol Premedication. Gynecol Oncol; 69:122-124, 1998

26. Micha, JP; Brown, JV: Primary Surgical Cure of Stage III-B Cervical Carcinoma with Adnexal Metastasis. Gynecol Oncol; 71: 317-319, 1998

27. Micha, JP; Rettenmaier, MA; Francis, L; Willenberg, R; Brown, JV: “Medically Necessary” Panniculectomy to Facilitate Radical Pelvic Surgery in Morbidly Obese Patients. Gynecol Oncol; 69:237-242, 1998

28. Brown JV, Rettenmaier MA, Dillman R, Birk C, Culkin, K, Micha, JP: Three hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer. Gynecol Oncol. 1998; 68:166-168.

29. Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RO, Smith MR, Drescher CW, Micha JP. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol 2000; 79:495-498.

30. Brown JV, Peters WA, Rettenmaier MA, Graham CL, Smith MR, Drescher CW, Micha JP. Three-consecutive-day topotecan is an active regimen for recurrentepithelial ovarian cancer. Gynecol Oncol. 2003; 88:136-40.

31. Micha JP. Expanding research infrastructure. The Women’s Oncology Review 2003; 3:177-178.

32. Micha,JP, Goldstein BH, Hunter JV, Rettenmaier MA, Brown JV. Long-term survival in an Ovarian Cancer Patient with Brain Metastases: A Case Report: Gynecol Oncol 2004;92:978-80.

33. Rettenmaier MA, Goldstein BH, Brown JV, John CR, Micha, JP. Impact of gynecologic oncologists in the care of uterine malignancies at a community hospital. Intl J Gynecol Surg 2004; 20: 57-63.

34. Micha JP, Goldstein BH, Rettenmaier MA, Brown JV. Cecal Pelvic Transposition Following Total Pelvic Exenteration. Gynecol Oncol 2004; 94:589-92.

35. Brown JV, Goldstein BH, Rettenmaier MA, Michelle MM, Graham CL, Micha JP. Laser ablation of surgical margins following excisional partial vulvectomy for vulvar intraepithelial neoplasia may decrease recurrences. J Repro Med 2005;50:345-350.

36. Micha JP, Goldstein BH, Rettenmaier MA, Mattison JA, Graham C, Birk CL, Brown JV Pilot Study of Outpatient Paclitaxel, Carboplatin and Gemcitabine for Advanced Stage Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer Gynecol Oncol 2004; 94:719-724.

37 Micha JP, Goldstein BH, Mattison JA, Bader K, Graham C, Rettenmaier MA, Brown JV, Markman M. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol 2005;96:132-5.

38. Micha JP, Goldstein BH, Rettenmaier MA, Brown JV Abdominal/Pelvic Coccidioidomycosis. Gynecol Oncol 2005; 96; 256-258.

39. Brown JV, Goldstein BH, Duma CM, Rettenmaier MA, Micha JP.Gamma-Knife Radiosurgery for the Treatment of Ovarian Cancer Metastatic to the Brain. Gynecol Oncol 2005; 97; 858-61.

40. Micha JP, Goldstein BH, Bock BV, Rettenmaier MA, Brown III JV. Spontaneous Bacterial Peritonitis. Intl J Gynecol Cancer 2006; 16: 908-911.

41. Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV, John CR, Markman M. Surgery Alone or Surgery with a Combination Radiation or Chemo-Radiation for Management of Patients with Bulky Stage 1B2 Cervical Carcinoma. Intl J Gynecol Cancer 2006; 16: 1-5.

42. Rettenmaier MA, Goldstein BH, Epstein HD, Brown III JV, Micha JP Serous psammocarcinoma of the ovary: An unusual finding. Gynecol Oncol 2005; 99:510-1

43. Rettenmaier MA, Goldstein BH, Stallman JM, Brown III JV, Micha JP. Greatly Elevated Serum CA-125 Level in a Patient with a Ruptured Endometrioma. J Gynecol Surg 2005; 21:109-112.

44. Rettenmaier MA, Goldstein BH, Brown III JV, Van Horn D, Micha JP. Recurrent gestational trophoblastic disease following persistently normal hCG titers: A rare occurrence. Am J Clin Oncol 2007; 30: 99-100.

45. Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV. A Rare Case of Coccygeal Endometriosis. Obstet Gynecol 2006; 107:1-2.

46. Micha, JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown III JV. Abraxane in the Treatment of Ovarian Cancer: The Absence of Hypersensitivity Reactions. Gynecol Oncol 2006; 100: 437-438.

47. Brown JV 3rd, Goldstein BH, Rettenmaier MA, Aylward MM, Graham CL, Micha JP.Laser Ablation of Surgical Margins After Excisional Partial Vulvectomy for VIN.Obstet Gynecol Surv 2005;60:584-5.

48. Rettenmaier MA, Goldstein BH, Stallman JM, Brown III JV Micha JP. Lymphoepithelial carcinoma of the cervix: Review and Treatment Course. J Gynecol Surg 2006; 21: 185-88.

49. Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV Pelvic Radiation Necrosis and Osteomyelitis Following Treatment for Advanced Cervix Carcinoma. Gynecol Oncol 2006; 101: 349-352.

50. Rettenmaier MA, Goldstein BH, Epstein HD, Brown Vaginal Reconstruction Following Supra-Levator Total Pelvic Exenteration. Gynecol Oncol 2006; 102: 397-399.

51. Micha JP, Goldstein BH, Epstein HD, Rettenmaier MA, Brown JV. Ovarian Cancer Metastatic to the Breast. Gynecol Oncol 2006; 102: 386-390.

52. Rettenmaier MA, Goldstein BH, Haghighi B,Brown III JV, Micha JP Serous endometrial intraepithelial carcinoma: Diagnosis and clinical management. J Gynecol Surg 2006;22: 69-72.

53. Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV. Neo-vagina Reconstruction Utilizing the Bladder and Urethra Following Radical Radiation Therapy. J Gynecol Surg 2006;22:73-75.

54. Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV. A response to Batt in A rare case of precoccygeal endometriosis. Obstets Gynecol 2006; 108:213-214.

55. Micha JP, Goldstein BH, Rettenmaier MA, Oglevie S, Lindsay SF, Haskell R, Brown JV III. Subclavian arterial puncture repair with Angio-Seal deployment. Gynecol Oncol 2007; 104: 761-3.

56. Micha JP, Goldstein BH, Epstein HD, Rettenmaier MA, Doering R, Brown III JV. A Precarious Case of Multiple Enlarged Arteriovenous Malformations in the Uterus. J Gynecol Surg 2007; 23: 23-29.

57. Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham CL, Bader K, Lopez KL, Nickle M, Brown JV. A Phase II Study of Outpatient First Line Paclitaxel, Carboplatin and Bevacizumab for Advanced Stage Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer. Intl J Gynecol Cancer 2007;17: 1-6.

58. Micha JP, Goldstein BH, Brown JV, Birk C, Van Horn D, Rettenmaier MA. Tuberculosis Mimicking Cervical Carcinoma. Accepted to Euro J Gynecol Oncol 2007.

59. Micha JP, Goldstein BH, Rettenmaier MA, Tinnerman-Minailo E, Brown JV, McCllellan S, Bock BV. Recurrent Vulvar Lymphangitis Cured with Vulvectomy in a Cervical Carcinoma Patient. Accepted to J Reprod Med 2007.

60. Rettenmaier NB, Rettenmaier CR,Wojciechowski T,Abaid LN, Brown JV 3rd, Micha JP, Goldstein BH. The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review.  Br J Cancer 2010;103:1657-62

61. Abaid LN, Goldstein BH, Lopez KL, Micha JP, Brown JV, Rettenmaier MA, Markman M. The Prognostic Significance of Optimal Debulking in the Setting of a Complete Clinical Response for Advanced Ovarian Carcinoma Patients Receiving Maintenance Chemotherapy. Arch Gynecol Obstet 2011; 283: 1127-1131.

62. Mendivil AA, Abaid LN, Epstein HD, Rettenmaier MA, Brown JV III, Micha JP, Wabe MA, Goldstein BH. Paget’s Disease of the Vulva: A Clinicopathologic Institutional Review. Int J Clin Oncol 2012; 17:569-74.

63. Mendivil A, Rettenmaier MA, Cox C, Abaid LA, Brown JV, Micha JP, Lopez KL, Goldstein BH. Acute and Delayed Complications from Surgery and Adjuvant Radiotherapy in the Treatment of High Risk Endometrial and Cervical Cancer. 2011 Oncology, 81:79-83.

64. Abaid LN, Rettenmaier MA, Brown III JV, Micha JP, Mendivil AA, Wabe MA, Goldstein BH. Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer.  J Gynecol Oncol 2012; 23: 22-27.

65. Rettenmaier MA, Mendivil AA, Brown JV III, Abaid LN, Micha JP, Goldstein BH. Same Day Discharge in Clinical Stage 1 Endometrial Cancer Patients Treated with Total Laparoscopic Hysterectomy, Bilateral Salpingoophorectomy and Bilateral Pelvic Lymphadenectomy. Oncol 2012;82:321-326

66. Mendivil AA, Abaid L, Epstein HD, Rettenmaier MA, Brown JV 3rd, Micha JP, Wabe MA, Goldstein BH. Paget’s disease of the vulva: a clinicopathologic institutional review. Int J Clin Oncol 2012; 17:569-74.

67.Del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2012;126:369-74.

68. Micha JP, Mendivil AA, Cupp JS, Goldstein BH. Recurrent Lymphatic Ascites in a Patient Cured of CervicalCarcinoma. Gyn Oncol 2012; 2: 105-106.

69. Mendivil AA, Micha JP, Brown JV 3rd, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH. Increased incidence of severe gastrointestinal events with first-line Paclitaxel, Carboplatin, and Vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2013;23:533-9.

70. Micha JP, Brown JV, Rettenmaier MA, Abaid LN, Mendivil AA, Lopez KI, Goldstein BH. Pegfilgrastim safely administered on the same day as dose-dense chemotherapy for patients with advanced-stage ovarian cancer. Clin Oncol 2013; Feb (letter).

71. Micha JP. Clinical Research and the Disparities Amongst Non-Profit Cancer Foundations. J Women’s Health

72. Abaid LN, Micha JP, Rettenmaier MA, Brown JV, Mendivil AA, Lopez KL, Goldstein BH. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma. Cancer Chemother Pharmacol 2013;72:101-107.

73. Mendivil AA, Brown III JV, Abaid LN, Rettenmaier MA, Micha JP, Wabe MA, Goldstein BH. Robotic-Assisted Surgery for the Treatment of Pelvic Masses in Pregnant Patients: A Series of Four Cases and Literature Review.J Robot Surg 2013; 7: 333–337. Care 2013; 2: 124.

74. Rettenmaier CR, Rettenmaier NB, Abaid LN, Brown JV, Micha JP, Mendivil AA, Wojciechowski T, Goldstein BH, Markman M. The Incidence of Genitourinary and Gastrointestinal Complications in Open and Endoscopic Gynecologic Cancer Surgery. Oncology 2014; 86:303-307

75. Mendivil AA, Micha JP, Stallman JM, Goldstein BH. A Very Rare Case of Vaginal Angiokeratoma. Euro J Gynaecol Oncol 2014; 3: 313-315.

76. Rettenmaier MA, Abaid LN, Brown JV 3rd, Mendivil AA, Micha JP, Goldstein BH. The incidence of postprandial nausea and nutritional regression in gynecologic cancer patients following intestinal surgery: A retrospective cohort study. Int J Surg 2014; 12: 783-787.

77. Brown JV, Mendivil AA, Abaid LN, Rettenmaier MA, Micha JP, Wabe MA, Goldstein BH. The Safety and Feasibility of Robotic Lymph Node Staging in Early-Stage Ovarian Cancer. Int J Gynecol Cancer 24(8) 2014.

78. Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Micha JP, Lopez KL, Goldstein BH. A comparison of open surgery, robotic assisted surgery and conventional laparoscopic surgery in the treatment of morbidly obese endometrial cancer patients. JSLS 2015;19: 1-5.

79. Rettenmaier MA, Mendivil AA, Abaid LN, Brown JV 3rd, Micha JP, Wilcox AM, Goldstein BH.
The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma. Arch Gynecol Obstet 2015; 291:1381-6.

80. Micha JP, Sassoon AF, Wong H, Goldstein BH. Prolonged Remission of Recurrent Cervical CarcinomaFollowing Paclitaxel and Carboplatin Chemotherapy with Paclitaxel Maintenance Chemotherapy. Anticancer Drugs 2015; 26:793-6.

81. Micha JP, Rettenmaier MA, Brown III JV, Mendivil AA, Abaid LN, Lopez KL, Goldstein BH. A randomized, controlled pilot study comparing the impact of aprepitant and fosaprepitant on chemotherapy induced nausea and vomiting in patients treated for gynecologic cancer. Int J Gynecol Cancer. 2016; 26:389-393.

82. Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Micha JP, Lopez KL, Goldstein BH. Survival rate comparisons amongst cervical cancer patients treated with an open, robotic-assisted or laparoscopic radical hysterectomy: A five year experience. Surg Oncol 2016; 25: 66-71.

 

PUBLICATIONS (NON-PEER REVIEW JOURNALS

1. Micha, JP: Genital warts. Treatable warning of cancer ? The Female Patient; 9:31-36, 1984.

2. Micha, JP: Interferon in refractory condyloma acuminata. Dermatology Times; 1985.

3. Micha, JP, Silva, PD: Condyloma acuminata and related HPV infections. The Female Patients; 11:43-58, 1986

PUBLICATIONS (ABSTRACTS)

1. Micha, JP; Stratton, JA; Senyei, AG; Braly, PS; Rettenmaier, MA; Berman, ML; DiSaia, PJ: The effect of tumor burden on tumor growth and response to chemotherapy in immunocompetent mice. Presented at the Society of Gynecologic Oncologist. Scottsdale, Arizona, February 1983.

2. Micha, JP; Rettenmaier, MA; DiSaia, PJ; Gupta, S: Immunologic and clinical assessment of interferon treated ovarian cancer patients. Presented at the Western Association of Gynecologic Oncologists. Colorado Springs, Colorado, May 1983.

3. Stratton, JA; Micha, JP; Braly, PS; Rettenmaier, MA; DiSaia, PJ: Correlation between chemosensitivity measured by the subrenal capsule tumor implant assay and the clinical response of patients with gynecologic tumors. Presented at the American Society of Clinical Oncologists. San Diego, California, May 1983.

4. Stratton, JA; Micha, JP; Braly, PS; Rettenmaier, MA; Berman, ML; DiSaia, PJ: The response of gynecologic tumors to chemotherapy; Correlation of the chemosensitivity predicted by subrenal capsule implants assay with the clinical responses of the patients. Proceedings of the Thirteenth International Congress of Chemotherapy, Vienna, Austria, 1983.

5. Micha, JP; Kucera, PR; Berman, ML; Romansky, S; Flamm, M; Reynolds, J; DiSaia, PJ: Malignant ovarian germ cell tumors: A review of 37 cases. Presented at the Society of Gynecologic Oncologists, Miami, Florida, February 1984.

6. Rettenmaier, MA; Braly, PS; Micha, JP; Kucera, PR; Silva, PD; Edwards, GS; Berman, ML; DiSaia, PJ: The use of permanent right atrial catheter in gynecologic cancer patients. Presented at the Felix Rutledge Society, Atlanta, Georgia, May 1984.

7. Micha, JP; Kucera, PR; DiSaia, PJ: Human lymphoblastoid interferon treatment of recurrent genital condyloma acuminata. University of California, Irvine, California, May 1984.

8. Kucera, PR; Micha, JP; Berman, ML; DiSaia, PJ; Creaman, WT; Boronow, R: Clinicopathologic assessment of uterine sarcoma patients. Presented at the Western Association of Gynecologic Oncologists, Sun River, Oregon, May 1984.

9. Rettenmaier, MA; Berman, ML; Braly, PS; Micha, JP; Kucera, PR; DiSaia, PJ: Skinning vulvectomy for treatment of vulvar intraepithelial neoplasia. Presented at the Western Association of Gynecologic Oncologists Thirteenth Annual Meeting, San Diego, California, June 1985.

10. Micha, JP; Kucera, PR; Sheets, EE; Rettenmaier, MA; DiSaia, PJ: Prophylactic Mezlocillin in patients undergoing radical hysterectomy. Presented at the Western Association of Gynecologic Oncologists Thirteenth Annual Meeting, San Diego, California, June 1985.

11. Kucera, PR; Sheets, EE; Micha, JP; Rettenmaier, MA; Berman, ML; DiSaia, PJ: Whole abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer. Presented at the Western Association of Gynecologic Oncologists Thirteenth Annual Meeting, San Diego, California, June 1985.

12. Micha, JP; Kucera, PR; DiSaia, PJ; Weck PK; Britt-Harrington, P: Human lymphoblastoid interferon treatment of recurrent condyloma acuminata. Presented at the Western Association of Gynecologic Oncologists Thirteenth Annual Meeting. San Diego, California, June 1985.

13. Kucera, PR; Sheets, EE; Bergen, S; Micha, JP; Weck, PK; Britt, PH; Olsen, EA; Trofatter, KF; DiSaia, PJ: Interferon (ALFA-N1) treatment of recurrent genital warts. A controlled trial of ibuprofen for symptomatic modification. Presented at the American Collect of Obstetricians and Gynecologists Meeting. Las Vegas, Nevada, April 1987.

14. Karram, MM; Tabor, B; Smotkin, D; Micha, JP; Bhatia, N; Wettstein, F: Detection of HPV DNA from vulvar dystrophies. International Society for the Study of Vulvar Disease. Broadbeach, Australia, August 1987.

15. Karram, MM; Bhatia, NN; Graur, N; Micha, JP: Efficacy of Mezlocilin versus Gentamicin/Clindamycin in the treatment of acute pelvic inflammatory disease. Poster Presentation. Annual American College of Obstetricians and Gynecologists Meeting. Boston, Massachusetts, April 1988.

16. Karram, MM; Tabor, B; Smotkin, D; Wettstein, F; Bhatia, N; Micha, JP: Detection of HPV DNA from chronic epithelial lesions of the vulva. Poster Presentation. Annual American College of Obstetricians and Gynecologists Meeting. Boston, Massachusetts, April 1988.

17. Brown, JV; Rettenmaier, MA; Micha, JP: A pilot study of oral etoposide for recurrent or persistent ovarian cancer. Western Association of Gynecologic Oncologists. June, 1992.

18. Brown, JV; Rettenmaier, MA; Micha, JP; Tullio, R; Burke, C: Taxol and Carboplatin is an effective outpatient regimen for advanced ovarian cancer. Western Association of Gynecologic Oncologists. June, 1995.

19. Micha, JP, Goldstein BH, Rettenmaier, MA, Mattison J, Graham CL, Birk CL, and Brown JV. Pilot Study of Outpatient Paclitaxel, Carboplatin and Gemcitabine for Advanced Stage Epithelial Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer. Eli Lilly Investigators Meeting March 2003, Phoenix, AZ.

20. Micha, JP, Goldstein BH, Rettenmaier, MA, Mattison J, Graham CL, Birk CL, and Brown JV. Paclitaxel, Carboplatin and Gemcitabine for Treatment of Advanced Stage Ovarian Cancer. Eli Lilly Investigators Meeting April 2004, Phoenix, AZ.

21. Micha JP, Goldstein BH, Rettenmaier MA, Bader K, Graham C, Lopez K, Nickle M, Genesen M, Brown JV III. Pilot Study of Outpatient Paclitaxel, Carboplatin and Bevacizumab for Advanced Stage Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer. Presented at the 11th Annual International Gynecologic Cancer Society Meeting, Santa Monica, CA; October 2006.

22. Abaid LN, Micha JP, Rettenmaier MA, Brown JV III, Mendivil AA, Lopez KL, Goldstein BH. A phase II study of modified dose-dense paclitaxel and every 4 week carboplatin for the treatment of advanced stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma. Society of Gynecologic Oncology 42nd Annual Meeting, Austin TX, March 24-27, 2012.

23. Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV III, Micha JP, Lopez KL, Goldstein BH. A Comparison of Open Surgery, Robotic-Assisted Surgery and Conventional Laparoscopic Surgery in the Treatment of Morbidly Obese Endometrial Cancer Patients. ESJO Annual Meeting; October 2013: Liverpool, UK.

24. Rettenmaier MA, Mendivil AA, Abaid LN, Brown III JV, Micha JP, Wilcox AM, Goldstein BH. Consolidation Hyperthermic Intraperitoneal Chemotherapy and Maintenance Chemotherapy FollowingLaparoscopic Cytoreductive Surgery in the Treatment of Ovarian Carcinoma. International Gynecologic Cancer Society Annual Meeting; May 2015: Santiago, CL.

25. Micha JP, Rettenmaier MA, Brown III JV, Mendivil AA, Abaid LN, Lopez KL, Goldstein BH. A phase IV, randomized study comparing the impact of aprepitant and fosaprepitant on chemotherapy induced nausea and vomiting and activities of daily living in patients treated for gynecologic cancer. European Society of Gynaecological Oncology Annual Meeting; October 2015: Nice, FR.

 

EDITORIAL REVIEW BOARDS

International Journal of Gynecological Surgery Anti-Cancer Drugs BMC Cancer European Journal of Surgical Oncology

SCIENTIFIC EXHIBITS Micha, JP; Edminster-Hughes, C: Interferon in the treatment of condyloma acuminata and related human papillomavirus disease. Presented at the Annual Meeting of the American Academy of Dermatology. Washington, D.C., 1984; and The American College of Obstetricians and Gynecologists, Washington, D.C., 1985.

Updated 03/07/07